Merck Sharp + Dohme Corp.

Neuromed Pharmaceuticals Ltd.

Pengcheng Patrick Shao

Feng Ye

Petr Vachal

Wanying Sun

Stephane L Bogen

Feroze Ujjainwalla

Zhicai Wu

David L Sloman

Jian Liu

Michelle R Machacek

Nunzio Sciammetta

Matthew Lloyd Childers

Christian Fischer

John W Lampe

Dann LeRoy Parker, Jr

Francesc Xavier Fradera Llinas

Alexander J Kim

Chunhui Huang

Yang Yu

Revathi Reddy Katipally

Daniel R McMasters

Michael Hale Reutershan

Craig R Gibeau

Deyou Sha

Qingmei Hong

J Michael Ellis

Sara Esposite

Andrew William Stamford

Tesfaye Biftu

Jared N Cumming

Prasun K Chakravarty

David James Witter

Xianhai Huang

Jack D Scott

Hongjun Zhang

Ulrich Iserloh

Rui Liang

Joshua Close

Yusheng Xiong

Solomon D Kattar

Ryan D Otte

Purakkattle J Biju

Derun Li

Santhosh Francis Neelamkavil

Hassan Pajouhesh

Lei Chen

Catherine M White

Peter H Fuller

Tanweer A Khan

Yanbing Ding

Joseph Leslie Duffy

Angela Dawn Kerekes

Min K Park

Sriram Tyagarajan

Hyewon Youm

Claire Lankin

Kake Zhao

Jonathan E Wilson

Jason Eugene Imbriglio

Dawn Marie Hoffman

Arto D Krikorian

Jayanth Thiruvellore Thatai

Venukrishnan Komanduri

Anthappan Tony Kurissery

Valdimir Simov

Jayanth Thiruvellore Thatal

Arto K Krikorian

Sujit Kumar Sarkar

Dann L Parker

Joseph L Duffy

Daniel R Mcmasters

Dawn M Hoffman

The present invention relates to Compounds of Formula I: and pharmaceutically acceptable salts or prodrug thereof. The present invention also relates to compositions comprising at least one compound of Formula I, and methods of using the compounds of Formula I for treatment of cardiometabolic diseases including high blood pressure, heart failure, kidney disease, and diabetes in a subject.

Natriuretic peptide receptor a agonists useful for the treatment of cardiometabolic diseases, kidney disease and diabetes

The present invention is directed to tricyclic compounds of formula (I) which are inhibitors of one or more mutant IDH enzymes (I); wherein A is &#x2014;C(R)&#x2550; or &#x2014;N&#x2550;; and X is selected from the group consisting of: (II-i), and (II-ii). The present invention is also directed to uses of the tricyclic compounds described herein in the potential treatment or prevention of cancers in which one or more mutant IDH enzymes are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such cancers. 

Tricyclic compounds as inhibitors of mutant IDH enzymes

The present invention is directed to tricyclic compounds of formula (I) which are inhibitors of one or more mutant IDH enzymes: (I). The present invention is also directed to uses of the tricyclic compounds described herein in the potential treatment or prevention of cancers in which one or more mutant IDH enzymes are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such cancers. 

The present invention is directed to tricyclic compounds of formula (I) which are inhibitors of one or more mutant IDH enzymes: (I); wherein A is &#x2014;C(R1)= or &#x2014;N&#x2550;; and X is selected from the group consisting of: (II-i), (II-ii), (I) (II-iii), and (II-iv). The present invention is also directed to uses of the tricyclic compounds described herein in the potential treatment or prevention of cancers in which one or more mutant IDH enzymes are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such cancers. 

Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, wherein D1, D2 and D3 are each N, CH, or substituted CH, are CETP inhibitors and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. 

Monocyclic isoxazolines as inhibitors of cholesterol ester transfer protein

Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, wherein X is &#x2014;C(&#x2550;O) or &#x2014;S(O)&#x2014;, are CETP inhibitors and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. 

Bicyclic ureas and thiadiazolidine-1, 1-dioxides as CETP inhibitors

Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, wherein X is (CH) or O, are CETP inhibitors and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis: 

Fused bicyclic isoxazolines as inhibitors of cholesterol ester transfer protein

In its many embodiments, the present invention provides certain C5-spiro iminothiadiazine dioxide compounds, including compounds Formula (I): (structurally represented) or tautomers thereof, and pharmaceutically acceptable salts of said compounds, wherein R1, R2, R3, X, Y, s, ring A, RA, m, -L1-, and RL are as defined herein. The novel compounds of the invention are useful as BACE inhibitors and/or for the treatment and prevention of various pathologies related thereto. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use, including for the possible treatment of Alzheimer's disease, are also disclosed. 

C6-spiro iminothiadiazine dioxides as BACE inhibitors, compositions, and their use

Thiazolidinone compounds, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis.

Therapeutic thiazolidinone compounds

Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. 

Fused bicyclic oxazolidinone CETP inhibitor

A series of substituted aryl sulfone derivatives represented by Formula I, or pharmaceutically acceptable salts thereof. Pharmaceutical compositions comprise an effective amount of the instant compounds, either alone, or in combination with one or more other therapeutically active compounds, and a pharmaceutically acceptable carrier. Methods of treating conditions associated with, or caused by, calcium channel activity, including, for example, acute pain, chronic pain, visceral pain, inflammatory pain, neuropathic pain, urinary incontinence, itchiness, allergic dermatitis, epilepsy, diabetic neuropathy, irritable bowel syndrome, depression, anxiety, multiple sclerosis, sleep disorder, bipolar disorder and stroke, comprise administering an effective amount of the present compounds, either alone, or in combination with one or more other therapeutically active compounds.

Substituted aryl sulfone derivatives as calcium channel blockers

Growing community of inventors

Fanwood, NJ, United States of America

Pengcheng Patrick Shao